Skip to main content
. Author manuscript; available in PMC: 2020 Nov 20.
Published in final edited form as: Bioconjug Chem. 2019 Oct 22;30(11):2947–2957. doi: 10.1021/acs.bioconjchem.9b00640

Figure 1.

Figure 1.

Structures of PR-targeted MR contrast agents and untargeted controls. Each of the targeted agents contains a progesterone derivative for targeting, a linker arm, and a Gd(III) chelate for MR imaging.